April 22, 2021
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Author
April 19, 2021
EC approves Sanofi’s Sarclisa to treat relapsed multiple myeloma
The European Commission (EC) approved Sanofi’s Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.…
April 14, 2021
AstraZeneca’s non-small cell lung cancer approved in China
AstraZeneca’s Tagrisso has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor…
April 14, 2021
FDA pauses vaccination with J&J vaccine after six cases of blood clot
U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
April 13, 2021
Drug testing approach uncovers effective combination for treating small cell lung cancer
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small…
April 12, 2021
Bayer:Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed iNHL
Bayer announced results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant progression-free survival (PFS) benefit for…
April 12, 2021
Sanofi acquires Tidal Therapeutics
Sanofi has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming…
April 1, 2021
J&J answers allegations over vaccine problems
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
April 1, 2021
FDA approves Sanofi’s Sarclisa to treat relapsed multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the…
March 31, 2021
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA’s human medicines committee (CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines…